Difference between revisions of "Daunorubicin liposomal (DaunoXome)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (16 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. | + | Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.<ref name="insert">[http://daunoxome.com/downloads/DaunoXome%20PI.pdf Daunorubicin liposomal (DaunoXome) package insert]</ref><ref>[[:File:Daunorubicinliposomal.pdf | Daunorubicin liposomal (DaunoXome) package insert (locally hosted backup)]]</ref><ref>[http://daunoxome.com DaunoXome manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
| − | ==Diseases for which it | + | ==Diseases for which it was used== |
| − | *[[Acute myeloid leukemia]] | + | *[[Acute myeloid leukemia - historical|Acute myeloid leukemia]] |
| − | *[[ | + | *[[Kaposi sarcoma - historical|Kaposi sarcoma]] |
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/druginfo/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/daunorubicin-liposomal.aspx Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-citrate-liposomal-patient-drug-information Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1996-04-08: Initial FDA approval as a first-line cytotoxic therapy for the treatment of advanced, HIV-associated [[Kaposi sarcoma|Kaposi's sarcoma (KS)]]. ''(Based on Gill et al. 1996)'' |
==Also known as== | ==Also known as== | ||
| Line 27: | Line 27: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Irritant | + | [[Category:Irritant]] |
[[Category:Liposomal chemotherapy]] | [[Category:Liposomal chemotherapy]] | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
| − | [[Category:Acute myeloid leukemia medications]] | + | [[Category:Acute myeloid leukemia medications (historic)]] |
| − | [[Category: | + | [[Category:Kaposi sarcoma medications (historic)]] |
| − | [[Category: | + | [[Category:FDA approved in 1996]] |
| + | [[Category:Discontinued drugs]] | ||
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it was used
Patient drug information
- Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)[4]
- Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1996-04-08: Initial FDA approval as a first-line cytotoxic therapy for the treatment of advanced, HIV-associated Kaposi's sarcoma (KS). (Based on Gill et al. 1996)
Also known as
- Generic name: daunorubicin citrate liposome injection
- Brand name: DaunoXome
References
- ↑ 1.0 1.1 Daunorubicin liposomal (DaunoXome) package insert
- ↑ Daunorubicin liposomal (DaunoXome) package insert (locally hosted backup)
- ↑ DaunoXome manufacturer's website
- ↑ Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)
- ↑ Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)